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1Chapter
Pharmaceutical Projects: Walking 
along the Risk Management Line
Jordi Botet
Abstract
We manage risk so commonly (and unconsciously) in our everyday life that we 
tend to undervalue it. Risk management was officially introduced in the pharma-
ceutical world by the ICH guideline Q9 in 2005. Since then, it has been intensively 
used and, not infrequently, misused. Practice shows that risk assessment tools are 
often seen as an end in themselves, while such important things as brainstorming 
on the matter and getting to know the problem are underestimated. A pharma-
ceutical project provides a very good example of this: risk management is critical, 
but as there are many unknown factors, it has to be performed in a way that what 
really counts is understanding the problems we face. A pharmaceutical project has 
at least two actors, a pharmaceutical firm and an engineering company, possess-
ing different backgrounds, and this often leads to different approaches. This may 
explain why risk management is not used as much as it should in pharmaceutical 
projects. Thus, this chapter considers a pharmaceutical project from the point of 
view of risk management.
Keywords: quality, pharmaceutical laboratory, engineering company, risk assessment 
tool, pharmaceutical quality system (PQS), life cycle, risk ranking and filtering 
(RRF), primary hazard analysis (PHA), biological agent
1. Introduction
Quality is not a matter of discussion. Quality is necessary for any manufactured 
product. Failures mean losses in terms of money, logistics, and prestige, and no 
industry can withstand these damages. Pharmaceutical products share this situa-
tion, but, besides, their lack of quality turns out to be a public health problem. This 
is why the authorities require that medicines meet their specifications and manufac-
turers have the responsibility of exclusively commercializing products possessing 
their purported quality.
The production of medicines is in fact composed of two different types of 
manufacture. Firstly, there are facilities that produce the ingredients, or active 
pharmaceutical ingredients (APIs), used in the preparation of the medicines. 
Secondly, we have those facilities, which combine the ingredients to obtain phar-
maceutical forms. These latter are packed to get what we know as a drug, medicine, 
or pharmaceutical. This chapter focuses on this second type of manufacture, 
although we consider biotechnology too (in spite of producing substances, which 
are used as ingredients).
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2. How to ensure quality
Taking for granted that medicines should always meet their specifications, 
we should find a reliable method for ensuring this. Unfortunately, guaranteeing 
quality is not an easy task, and this explains why over time different strategies have 
been applied.
The oldest one, which we might term as “analytical quality,” proposed the 
analysis of the finished products as the tool for determining their appropriateness. 
This approach has many flaws, just to mention one, the quality problem is just 
detected when the product is already finished (and this makes corrective measures 
very difficult).
Then, in the middle of the twentieth century, “manufactured quality” was 
introduced. This new methodology, which led to the publication of the well-known 
GMP (good manufacturing practices), is based on the assumption that quality 
should be considered as another ingredient of the product (this was termed as 
“built-in quality”).
More recently, already in the twenty-first century, the International Council 
for Harmonization (ICH) has extended this latter approach to the development 
stages of the product in order to attain a complete control of its life cycle. The logic 
underlying this method is very simple. How can you manufacture a quality that you 
have not designed previously? This is why we came to the present situation, which 
considers that quality is something that you should design (quality by design), con-
struct (built-in quality), and supervise (process and product monitoring). In order 
to attain these goals, it is necessary to define and implement a policy of quality, 
which requires the establishment of a quality system. Although different systems 
are possible, in 2008, the ICH proposed a pharmaceutical quality system (PQS), 
specially developed for the pharmaceutical industry [1].
Even though the PQS focuses on pharmaceuticals, it is evident that if we are 
bound to produce quality products, the unit where we manufacture them should 
share this same approach for quality and here, the PQS provides very useful hints 
regarding the quality of pharmaceutical projects.
3. About the pharmaceutical project
A pharmaceutical project can be defined as a temporary effort undertaken with 
the aim of creating facilities that allow manufacturing medicines with the required 
quality and assurance. This effort is usually a quite difficult one, because it has to be 
carried out by different partners, which should work together, even if pertaining to 
different technical areas.
The partners who take part in a project belong normally to two groupings. On 
one side, the “client” (that is, the pharmaceutical laboratory or, maybe, laboratories) 
desires to possess new manufacturing premises or modify old existing ones. On the 
other side, the “supplier” usually consists of an engineering company that in fact 
coordinates different suppliers, extending from the providers of construction mate-
rials and associated services to the sellers of pharmaceutical equipment. These two 
parts, which to simplify matters we are going to name from now on as “laboratory” 
and “engineering,” are usually sharply asymmetric. The laboratory in these mat-
ters, generally speaking, has a much more limited experience than the engineering, 
whereas the knowledge regarding pharmaceutical norms is often less developed in 
the engineering. The amount and importance of these differences can vary a lot, but 
here we have a possible source of problems that should not be overlooked and that 
makes very advisable tight control on a project.
3Pharmaceutical Projects: Walking along the Risk Management Line
DOI: http://dx.doi.org/10.5772/intechopen.82601
4. Structure of a pharmaceutical quality system (PQS)
The paradigm of quality described by the ICH guidelines, Q8 to Q12 [1, 2–5], 
should also be applied to pharmaceutical projects, but taking into account the 
existing differences between manufacturing and managing a project. This is why 
not all the elements of a quality system devised for products can be applied into a 
pharmaceutical project. Let us analyze this (Figure 1).
The development and implementation of a PQS is the result of the definition of a 
quality policy by a laboratory. In order to put this policy into practice, the company 
writes a quality manual and associated documents that develop it in more detail. A 
quality manual should address the following topics:
1. The PQS is devised to ensure the application of GMP by the laboratory. As 
shown in Figure 1, the PQS covers the whole life cycle of a medicine, excluding 
the stage of development (this is the consequence of an old tradition of work-
ing in development centers and of the difficulty of applying the strict controls 
of GMP to a development laboratory).
2. Management responsibilities should be clearly stated. Practice shows that this is 
very important. As in old battles, the army can only win the war if there is a (good) 
chief leading it.
3. ICH Q10 describes two capacitors, intended to help in the task of reaching the 
objectives. The first one is risk management and we will discuss it in detail 
further on, as the main topic of this chapter. The second one is knowledge 
management and its intent is fighting the very pernicious practice that rules in 
more than one company: that is, people who get some knowledge on products 
Figure 1. 
Structure of the PQS (ICH Q10).
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or processes do not inform the others, but keep it for them and, consequently, 
there is a continual loss of information.
4. The PQS contains four elements (Figure 1). All of them, albeit not in this 
form, are very important in a project.
5. Project life cycle
A life cycle approach is an important element for ensuring the global quality of 
a process. As mentioned before, quality has to be designed in order to be controlled. 
The term “designed quality,” applied to a pharmaceutical project, means that objec-
tives are well defined and that critical variables have been identified and quantified. 
This allows for a monitoring and evaluation of the project: if the critical variables 
are kept under control, then objectives will be met. Thus, the life cycle has to be 
considered as a chain of events that progressively increase the amount of informa-
tion and build quality gradually.
As it can be seen (Figure 2), the life cycle of a project is composed of four 
phases, although only the first two (design and realization) concern what we have 
been calling pharmaceutical project and are managed by the two partners. The 
latter two phases (manufacture and discontinuation) are just the consequence of 
the former two and they belong exclusively to the laboratory. In fact, instead of 
Figure 2. 
The pharmaceutical project within the project life cycle.
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“manufacture,” we can talk of “routine production,” where quality is the result 
of the quality of the project plus all the measures applied to build quality into the 
products and to monitor that this is correctly realized. The last phase, discontinua-
tion, is simply mentioned to remind us that when facilities have to stop production 
to be closed, this has to be done in an organized way (i.e., market cannot be left 
undersupplied by a unilateral decision; the environment has to be protected by 
recycling or disposing of materials in an ecological way, etc.).
6. Risk management
Figure 3 summarizes the basic definitions related with risk management, as 
described in guideline ICH Q9 [3]. In any activity, there are hazards, which are 
significant because they can turn into harms. It is evident that hazards matter 
because there is a chance that they materialize into harms, and it is obvious that the 
importance of the harm determines how much attention they deserve. Thus, it is 
easy to understand the definition of the risk.
There is no human activity free from hazards (and, unfortunately, from harms) 
and, consequently, risk is always extant. This is why we came to speak of risk 
management. As we always face risk, it is meaningful to understand it and try to 
diminish it. When we remove a dish from an (hot) oven, there is a hazard: we can 
burn our fingers. To diminish the risk, we use an oven glove. By donning a glove, 
we diminish the probability of the harm and, thus, the risk. And what about the 
severity of the harm? In general, it is considered that we cannot act against it, as 
the severity of a harm is an attribute of it. Anyway, we might also think that the 
simple fact of wearing a glove would diminish the severity of the burn. Yes, in the 
interpretation of risk, there is always some amount of personal understanding, but 
this is not very relevant if we come to appreciate the situation well and we apply the 
same criteria over time. Just to finish with these considerations, we should keep in 
mind that the exact assessment of risk is second to the accurate understanding of 
the hazard. This is why in many cases we need not determine risk but just assess the 
hazards (Which hazards exist? Which are their causes? Are they likely? After all, 
should we worry? Should we take any measure? etc.).
Figure 4 summarizes the different levels of risk or of hazard assessment (to 
express it in a different way). As we can see, the objective is always reducing the 
level of risk as much as possible. This reduction, however, should be consistent with 
the efforts, which we apply for attaining this effect. Sometimes, a high risk might be 
accepted if there is no better alternative.
Figure 3. 
Main definitions concerning risk management.
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There are several tools, which we can use for risk analysis [3]. They can be used 
and combined according to particular needs. In fact, the application of a standard 
method is necessary when high levels of formality are required (e.g., in comparative 
studies or in scientific papers), but for the routine risk assessment within a com-
pany, it is possible to be less formal and adapt the tools to better fit our needs. Tools 
just organize information. They do not improve our information (if our raw data are 
poor or inaccurate, the application of the best of tools will not mend them). Thus, 
the quality of a risk analysis depends mainly on how worth our information is and 
on the knowledge and experience of the person who performs the study.
Figure 5 lists the most common methodologies used in risk analysis. Among the 
specific ones, the most popular is, without any doubt, FMECA, an excellent tool 
when the process under study is well known. Then, it is possible to evaluate risk and 
use its value as an indicator for process improvement. Anyway, in most cases, when 
the amount of knowledge is more modest, it is better to start with PHA. HACCP is 
a very good tool for the control of processes; in fact, the WHO recommends it for 
Figure 4. 
Risk.
Figure 5. 
Risk analysis tools.
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the control of pharmaceutical manufacturing processes [6]. It is not necessary to 
add that HACCP requires a deep knowledge on the process. FTA is useful to identify 
the root causes of a problem. HAZOP can help to identify possible problems related 
to equipment and operation involved in a process. RRF is the choice tool for the 
comparison of items composed of different elements.
Next to the specific methodologies, we can talk of unspecific ones. Properly 
speaking they are not risk analysis tools but provide information, which is critical 
to perform an analysis. Here, we should emphasize flowcharts, which are a key 
element to start a risk analysis of a process.
For the risk management of pharmaceutical projects, we select, besides flowcharts, 
RRF and PHA. This is why, we consider useful to provide some guidance on them.
Flowcharts are very useful to get a clear idea of a process and to perform a haz-
ard assessment. In fact, the layout of a pharmaceutical unit is the translation of the 
flowchart steps into premises. The example of flowchart, which we present here in 
Figure 6, covers in a simplified way the operational stages of a pharmaceutical unit. 
It is evident that in practice there can be different types of processes.
RRF (Figure 7) is a tool conceived for the comparison of different items, pos-
sessing different types of hazards and risk levels, by reducing them to a common 
denominator. The application of RRF starts by identifying the items to be compared 
and identifying their components and subcomponents. Then, the risk factors are 
determined and their integration allows for the establishment of the global risk 
of the item. As shown in Figure 7, all Rf are given the same weight and, thus, the 
load of each component depends more on the number of Rf considered than on the 
importance of the component itself. This can be corrected, for example, by giving a 
higher classification of risk to single Rf or to all the Rf of a given component.
Figure 6. 
Flowchart summarizing the steps of pharmaceutical manufacture.
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Stage/
subject
Possible 
hazard
Hazard 
cause
Possible effect 
(harm)
Is hazard 
significant?
Control 
measures
□ Yes/□ No
□ Yes/□ No
Table 1. 
Example of chart used to develop PHA.
PHA is very practical for the analysis of situations where there is still limited 
information. PHA uses charts like the one shown in Table 1 (although, often, 
the column describing the effect can be omitted, because it does not provide any 
useful information).
Figure 7. 
Summary of steps for the realization of RRF.
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Practice shows that, while performing risk analysis, one of the points that 
creates more confusion is the clear distinction among hazard, cause of the 
hazard, and effect of the hazard (harm). To simplify this matter, we propose the 
following approach.
We establish six types of hazards as the base of our analysis (Figure 8), then we 
apply them to the item that we study and we determine if this hazard might exist. If 
it really exists, then it is easier to establish possible causes and their derived effects 
and to propose control measures.
7. Pharmaceutical project management
7.1 Supplier selection
It is not necessary to insist on the fact that the selection of the partner with 
whom a laboratory will realize a project is very important. Following, we provide a 
simplified example of application of RRF.
Component (1) “Quality”
Rf 1.1 = quality system; Rf 1.2 = training program; Rf 1.3 = realization of com-
missioning; Rf 1.4 = support for qualification; etc.
Component (2) “Reliability”
Rf 2.1 = experience in projects; Rf 2.2 = amount and completeness of documen-
tation; Rf 2.3 = fulfillment of scheduled requirements; etc.
Component (3) “Accessibility”
Rf 3.1 = number of people in the company; Rf 3.2 = distance of the nearest point 
of service of the company to the project site; Rf 3.3 = knowledge of the language of 
the site; Rf 3.4 = after sale service; etc.
Component (4) “Budget”
Rf 4.1 = price; Rf 4.2 = payment conditions; Rf 4.3 = bonuses; etc.
After determining the risk factors for each component, they are used to calculate 
its comprehensive risk.
Then, the global risk of each item is evaluated adding the risks of their 
components.
Finally, the items are ranked according to their respective risk. Thus, they can be 
compared. They can also be “filtered,” that is, selected (Figure 6).
7.2 Translation of the URS into a plan
As shown in Figure 9, a pharmaceutical plan is the practical translation of the 
requirements set up in the URS.
The conditions penned in the URS depend on the particular wishes of each 
laboratory, whereas the plan to be developed and constructed by the engineering is 
Figure 8. 
Summary of hazards to be considered in PHA charts.
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encoded, by GMP [7–10] and good engineering practice (GEP). GEP is not codified 
as such. It is understood as the generally admitted good approach.
Let us analyze, using a risk management approach, the requirements that should 
meet a project. We use an adapted form of PHA.
7.2.1 Hazard #1: (external) contamination
In Table 2 are described the main causes of (external) contamination and the 
control measures to keep them at bay.
7.2.2 Hazard #2: cross-contamination
In Table 3 are described the main causes of cross-contamination and the control 
measures to hold them at bay.
Figure 9. 
The pharmaceutical project: URS and their translation.
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7.2.3 Hazard #3: error/mix-up
Table 4 evaluates the main causes of error/mix-up and provides control mea-
sures. Although error/mix-up appears because of the inefficiency of personnel (and 
this means that their prevention is based on training), an improved design of the 
premises diminishes their probability. Adequate flows and sufficient working space 
should always be considered in a project.
7.2.4 Hazard #4: degradation
Materials and products are damaged when exposed to inadequate conditions. 
Table 5 summarizes control measures.
7.2.5 Hazard #5: equipment malfunction
During routine production, equipment is submitted to a maintenance plan to 
avoid malfunction. During the project, however, equipment has to be well sited and 
mounted, as summarized in Table 6.
7.2.6 Hazard #4: health, safety, and environment
The denomination health, safety, and environment (HSE) covers all the aspects 
that can affect the health and security of personnel and the environment. Table 7 
describes actions to control them.
Cause Control measures
Inadequate siting of the building Pharmaceutical units should not be located in contaminated areas
Insufficient tightness of the 
premises
Ensure isolation of premises from the outside (sealed panels, floors, 
and windows)
Access to premises by airlocks/changing rooms
Protection of premises from the entrance of insects, birds, and 
animals
Anticipate the placement of traps and baits
Inadequate separations Rest rooms and refectories should be separated from areas of 
production and quality control (QC) laboratory
Toilets should not have direct communication with the areas of 
production or storage
Maintenance workshops should be separated from the production 
areas
Parts and tools used for production should be kept in separate rooms 
or in lockers
Animal houses should be separated from the other areas
Dirty incoming materials Receiving and dispatch bays should be designed and prepared to 
allow the cleaning of the incoming containers
Access through drains Drains should be designed and built to prevent backflow
Inadequate air-handling Ventilation air should be HEPA-filtered
Animal houses should have separate air-handling systems
Premises should have overpressure (see the exceptions in Sections 7.3 
and 7.4) to prevent the entrance of unfiltered air from outside
Defective parts of equipment Parts of equipment coming into contact with materials and product 
should not affect them, neither be affected by them
Table 2. 
(External) contamination.
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Cause Control measures
Inadequate facility design Premises should be designed to allow for adequate cleaning and 
sanitization
Premises should be designed to avoid the build-up of dust and dirt
Repair and maintenance operations should not affect the quality of the 
products (e.g., performed from outside the clean rooms). Thus, there 
should be technical areas for equipment and a technical space over the 
working areas for ducting, lightning, etc.
The layout of the premises should allow the production to take place 
in areas connected in the logical sequence of the required levels of 
cleanliness (e.g., of classification)
Materials and products should only be exposed to the environment in 
clean rooms possessing sanitary design
Packaging areas should be designed and laid out to avoid 
cross-contamination
The QC laboratory should be designed to suit the operations
Inadequate tightness of the 
premises
Clean rooms should be tight to ensure adequate isolation (sealed 
panels, floors, and windows)
Inadequate separations Access to classified areas by specific airlocks/changing rooms
There should be an area for the sampling of starting materials
There should be an area for the weighing of starting materials
Risk of cross-contamination by highly active, toxic substances or 
biological agents should be controlled. See Section 7.3
The QC laboratory should be separated from the production areas
The QC laboratory areas where microbiological, biological, and 
radioisotope tests are performed should be separated from each other
Inadequate cleaning There should be an adequate cleaning area with adequate separations 
for equipment to be cleaned, cleaning area, drying area, and storage of 
clean equipment
Inadequate air-handling When operations are likely to generate dust (e.g., sampling, weighing, 
mixing, etc.), there should be measures to control it
Starting materials should be weighed in a special area provided with 
unidirectional flow and exhausting
Materials and products should only be exposed to the environment in 
clean rooms possessing appropriate air-handling
Recycled air should be HEPA-filtered
Pressure differentials should control the flows of air among clean 
rooms
The QC laboratory should possess an adequate separate air-handling 
system
The QC laboratory areas where microbiological, biological, and 
radioisotope tests are performed should possess separate air-handling 
systems
Inadequate equipment Equipment should be installed to avoid contamination
Washing, cleaning, and drying equipment should not be source of 
contamination
Whenever possible, closed equipment should be preferred
Table 3. 
Cross-contamination.
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Cause Control measures
Inadequate facility design Layout and design must aim to minimize the possibility of errors
Premises should be designed to be able to follow the logical flows of 
personnel and materials
The storage areas should allow for the orderly and sure storage of the 
different sorts of materials and products (“traditional warehouse”) or 
possess a computerized management system providing the same level 
of security (“chaotic warehouse”)
The layout of the premises should allow the production to take place 
in areas connected in the logical sequence of the operations
The areas should permit the orderly and local positioning of 
equipment and materials
In the production areas, there should be in-process storage rooms 
permitting to keep materials and equipment in an orderly way
Packaging areas should be designed and laid out to avoid mix-ups
The QC laboratory should have sufficient space
Inadequate separation The storage areas should ensure the segregation for items under 
quarantine, returned, rejected, and recalled. This separation can 
be assured by separated and closed areas or by a computerized 
management system providing the same level of segregation
The receiving and dispatch bays of the warehouse should be separated
Printed materials should be stored in a separate area with restricted 
access
Free access Personnel access to critical areas should be controlled and restricted
Inadequate marking Fixed pipework should be labeled to indicate contents and direction 
of flow (if this is necessary)
Rooms and equipment should be adequately identified
Inadequate illumination Working areas should be well lit
Inadequate placement of 
equipment
Equipment should be installed to avoid error and mix-up
Table 4. 
Error/mix-up.
Cause Control measures
Inadequate facility 
design
Receiving and dispatch bays should protect the products from the weather
Inadequate 
conditions
Acquire adequate information on the product requirements
Temperature and, if necessary, humidity in the production areas should be adequate 
and monitored
Electrical supply, lighting, temperature, humidity, and ventilation should not 
adversely affect the products
Storage areas should provide adequate conditions of temperature (and if necessary 
humidity) for the materials and products
Table 5. 
Degradation.
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Cause Control measures
Inadequate installation Perform commissioning/qualification
Equipment must be located to suit the operations
Inadequate separation Consider in the QC laboratory separate rooms for instrumentation, 
in accordance with their particular requirements
Table 6. 
Equipment malfunction.
7.3 Management of toxic substances
Sometimes commercial/logistic aspects determine from the outset the character-
istics of a pharmaceutical plant: typically, multiproduct facilities (when APIs are not 
particularly active and general GMP precautions suffice for ensuring that significant 
Cause Control measures
Inadequate installation Perform commissioning/qualification
Equipment must be located to suit the operations
Dangerous products Highly active, toxic substances or biological agents should be 
controlled (see Section 7.3)
There should be special storage areas, safe and secure, for: highly 
active, radioactive, narcotics, abuse, explosive, flammable, etc.
Dangerous biological agents Biological agents should be handled adequately (see Section 7.4)
There should be adequate equipment (freezers, refrigerators, etc.) 
for the maintenance of the biological agents
Inaccessibility/unhandiness Premises should be designed to suit the operations to be carried 
out
Changing rooms and toilets should be easily accessible and 
adapted to the number of users
Pipework, light fittings, ventilation points, and other services 
should be designed and placed to avoid the creation of recesses 
difficult to clean. And, as far as possible, they should be accessible 
from technical areas
Open channels should be avoided where possible, but if they are 
necessary, they should be shallow to facilitate cleaning
The QC laboratory should be designed to suit the operations
In the QC laboratory, there should be adequate space for the 
storage of samples, standards, solvents, reagents, and records
Current drawings of critical equipment and utilities should be 
maintained
Uncontrolled solid waste There should be adequate places for the storage of solid waste
There should be a place for the classification of solid waste
Uncontrolled effluents There should be a place for the treatment of liquid effluents 
(decontamination) prior to its release or transportation to a 
handling center
Dangerous gaseous effluents should be either filtered or 
incinerated
Table 7. 
HSE.
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cross-contamination will be excluded) or, less frequently, dedicated facilities, when 
logistic reasons recommend limiting the number of products in order to increase 
output. A quite different situation may arise when APIs can be deemed “toxic.” This 
term is used in a practical way to provide a general denomination for substances that 
possess high activity or potency (e.g., tiny amounts are needed to produce a pharma-
cological effect) or harmful effects (e.g., sensitization, genotoxicity, etc.).
When designing premises where toxic APIs will be handled, there has always 
existed a key question: is it correct if they are multiproduct or we should opt for 
dedicated ones? The response to this question cannot be general, because substances 
are diverse. The traditional approach was considering, roughly speaking, three 
cases. Firstly, we had the APIs, which could be deemed nontoxic and which, as we 
said before, could be produced in multiproduct facilities. Secondly, we had the APIs 
possessing high activity (e.g., hormones, cytostatics, certain antibiotics, etc.), which 
required dedicated facilities. And finally, we had two cases, which required strict 
segregation. This last group included live microorganisms and products possessing 
sensitizing or toxic effects (their action, properly speaking, cannot be quantified and 
should be considered as “on/off”), such as beta-lactam antibiotics [11].
In order to better clarify this group, it was proposed a scientific approach, which 
is summarized in Figure 10. The flowchart combines an EMA guideline on this mat-
ter [12] (upper part with a darker shade) with logistic criteria (lower part).
When it is spoken of single product or multiproduct facilities, their meaning 
appears evident, but what about dedicated facilities? This implies separation, but 
what kind of separation. Only risk management can provide an adequate answer 
to this question. Figure 11 describes the rationale of this approach. The rectangle 
represents the risk level (on the left lower part, the lighter color indicates low risk, 
whereas, on the right upper part, the darker color shows high risk). Thus, multi-
product facilities are adequate when risk is low, and segregated facilities are neces-
sary when risk is high. Then, in the middle, where risk can be deemed medium, it is 
possible to think of intermediate solutions (e.g., instead of separation of facilities, 
separation of products) or campaign production (e.g., separation is not physical but 
temporal). The severity of the hazard depends on the API, whereas the probability 
of occurrence is related to the way of manufacturing. In other words, once the 
“toxicity” of the API is known, the practical level of risk will depend on the produc-
tion techniques used for the manufacture of the products. Dedicated facilities mean 
more expensive projects, but at the same time lower risk of cross-contamination 
and, for instance, easier and surer cleaning validations [13].
7.4 Management of biological systems
Biotechnology implies the use of biological systems. Under this term, we 
design both cells and microorganisms. Most of them (in principle, the cells, and 
many microorganisms) do not pose any particular thread to personnel. In fact, the 
contrary is true. They are labile and very susceptible to contamination and require 
strict measures of control to keep them viable. There are, however, microorganisms, 
which suppose a thread for the personnel if they infect them during operations. 
These “biological agents” are internationally classified into four groups (Table 8) in 
function of the level of biosecurity (BSL) or protection level (PL) that they require 
[14, 15].
The project of a laboratory handling biological agents has to take into account its 
two types of requirements: on the one hand, those regarding in general a pharma-
ceutical laboratory and on the other, the particular necessities of facilities contain-
ing live microorganisms. We have already considered the former; thus, here we will 
exclusively discuss the latter.
Perspectives on Risk, Assessment and Management Paradigms
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Figure 11. 
Risk analysis rationale for defining the type of facilities.
Figure 10. 
Decision tree for facilities.
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In a laboratory where biological agents are cultured, these microorganisms 
suppose the “hazard”; the “cause” is the inadequacy of the measures taken to ensure 
that these agents will remain contained; and the “effect” is the infection of people by 
released agents. Thus, our risk analysis will focus on the control measures (Table 9).
Characteristic BSL/PL
1 2 3 4
Personal risk Minimal Low High Very high
Epidemic risk No No Low High
Therapy/prevention Unnecessary Available Available Unavailable
Manipulation Workbench Open 
hood
Biological 
safety cabin 
(BSC)
Isolator or 
BSC + personal 
protective equipment 
(PPE)
Table 8. 
The four groups of biological agents.
Element Control measures
Premises Area segregation
Ensure contention
Ensure possibility of disinfection
Operations can be seen from the outside
Easy communication with the exterior (e.g., interphone)
Ensure security in case of emergency (e.g., earthquake, flood, fire, etc.)
Air-handling system HEPA-filtered/sterilized exhausted air
Ensure depression (∆P−)
No recycling of air
Ingress Restricted access
Airlocks with interlocked doors
Pass-boxes with disinfection systems
Sterilizers provided with double doors
Separated changing rooms for entry and exit
Equipment/clean 
rooms
Ensure operation of critical equipment in case of power supply cut
Provide separation between agents and operators
Provide wash basins with hand-free taps
Vacuum tubes protected with HEPA filters or disinfectant traps
Waste Inactivation of “biowaste”
Inactivation of effluents
Labeling The international sign of biological 
hazard should be affixed at the entrance 
of the laboratory and at critical rooms 
and critical equipment (e.g., incubators, 
freezers, etc.).
Table 9. 
Control measures for biological hazard in the laboratory.
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In Table 9, we mention a series of elements that should be taken into account 
when designing a laboratory manipulating biological agents. The characteristics of 
these elements depend on the BSL/PL. This means that they might be unnecessary 
for level 1, just recommended for an intermediate level and required for a high level. 
It has to be studied case by case, using a risk management approach, which should 
analyze the level of risk and the level of protection provided for the systems in place.
8. Conclusions
Society requires medicines possessing the purported quality, and this is only 
possible if we design, manufacture, monitor, and control them adequately. These 
undertakings, however, involve appropriately devised, built, and qualified premises 
and facilities, which are the outcome of a project. A pharmaceutical project is a very 
complex subject because it involves at least two parts, with different visions and 
experience, and because it implies scores of suppositions and projections into the 
future. The risk of straying away from the expected roadmap is quite real. Thus, risk 
management becomes necessary. In a project, the amount of information is limited 
and thus, while using risk analysis tools, it is essential to bear in mind that what 
really matters is to understand which problems are at stake and to get a clear picture 
of their respective relevance. Once this is achieved, it is easier to provide adequate 
solutions. Risk is controllable, if we know and understand it!
A frequent problem, when trying to evaluate risk, is that information is so varied 
and multiform that it becomes difficult to ascertain, which are the hazards and 
distinguish them from, say, causes and effects, let alone the logical organization of 
the information. To overcome these difficulties, we propose two tiers of solutions: 
on one side, to use simple risk analysis tools focusing more on hazard and control 
measures than on risk quantification and on the other, to use defined simple quality 
hazards as the point of departure for the analysis.
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